- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06254664
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device
February 8, 2024 updated by: Xiromed LLC
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Zephir Inhaler Device
An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device.
Zephir inhaler robustness will be assessed by in vitro testing of the Zephir inhaler after 12 weeks of patient use
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 382210
- Cliantha Research
-
-
-
-
Florida
-
Fort Myers, Florida, United States, 33907
- Vanguard Clinical Research, LLC
-
Kissimmee, Florida, United States, 34744
- Clinical Research Solutions - Orlando
-
Miami, Florida, United States, 33176
- Vista Health Research
-
Miami, Florida, United States, 33173
- Research Institute of South Florida, Inc.
-
Miami, Florida, United States, 33145
- Clintex Research Group
-
Miami, Florida, United States, 33155
- My Preferred Research LLC
-
-
Rhode Island
-
Cranston, Rhode Island, United States, 02920
- Greater Providence Clinical Research, LLC
-
-
Texas
-
Cypress, Texas, United States, 77433
- Inquest Clinical Research, LL
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria (abbreviated):
- Capable of understanding the requirements, risks, and benefits of study participation, and as judged by the Investigator, capable of giving written informed consent.
- Male or non-pregnant female subjects between 40 to 75 years of age at Screening Visit (Visit 1) diagnosed with COPD.
- General good health (except the COPD diagnosis) and free of any concomitant conditions that would put the subject at increased risk during the study as per the discretion of the Investigator.
- An established physician diagnosis of COPD as defined by GOLD 2022.
- At Screening Visit, post-bronchodilator FEV1≤80% and ≥40% of predicted normal values as per Global Lung Function Initiative (GLI-2012) - and post-bronchodilator FEV1/FVC ratio ≤0.70.
Current COPD Therapy: Subjects must be on stable regimens of one of the following for at least 8 weeks prior to screening (Visit 1):
- Long-acting muscarinic antagonist (LAMA)
- LAMA+LABA
- Inhaled corticosteroids + LAMA
- Current or ex-smokers with ≥10 pack-year smoking history (Note: Pack- Year= (cigarettes smoked per day x years smoked)/20)).
- No occurrence of an upper or lower respiratory tract infection 14 days before Screening Visit.
- No COPD exacerbation, defined as any worsening of COPD requiring an emergency department visit or hospitalization, or the use of antibiotics (strong CYP450 3A4 inhibitors with ≥ 14 days of acute non-respiratory
- Ability to adequately use the Test inhaler.
Exclusion Criteria (Abbreviated):
- Treatment for mild-moderate COPD exacerbations within 4 weeks prior to the Screening Visit (Visit 1) or more exacerbations in the last year.
- Hospitalization for COPD or pneumonia within 12 weeks prior to the Screening Visit (Visit 1).
- History of a life-threatening COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest, hypoxic seizures, or mMRC (Modified Medical Research Council) dyspnea Grade 4.
- Acute (viral or bacterial) upper or lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, urinary tract infection or illness within 4 weeks prior to the Screening Visit (Visit 1).
- Subjects with a history of asthma or a clinical diagnosis of asthma, allergic rhinitis, or atopy; a total blood eosinophil count above 600/mm3.
- Historical or current evidence of a clinically significant disease
- Have any of the following conditions that, in the judgment of the Investigator, might cause participation in this study to be detrimental to the subject.
- A subject must not have any clinically significant, uncontrolled condition, or disease state that, in the opinion of the Investigator, would put the safety of the subject at risk through study participation.
- History of allergy or hypersensitivity to anticholinergic/muscarinic receptor antagonist agents, beta-2 adrenergic agonists, lactose/milk proteins, or specific intolerance to aerosolized tiotropium-containing products or its derivatives.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tiotropium 18 µg inhalation powder, hard capsule once daily (QD)
Interventions: Drug: Tiotropium 18 µg inhalation powder, hard capsule Device: Zephir inhaler |
Tiotropium 18 µg administered using Zephir inhaler
Tiotropium 18 µg administered using Zephir inhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
In vitro Measurement of Emitted Dose
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 3, 2022
Primary Completion (Actual)
July 7, 2023
Study Completion (Actual)
October 27, 2023
Study Registration Dates
First Submitted
January 30, 2024
First Submitted That Met QC Criteria
February 8, 2024
First Posted (Actual)
February 12, 2024
Study Record Updates
Last Update Posted (Actual)
February 12, 2024
Last Update Submitted That Met QC Criteria
February 8, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Respiratory Aspiration
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Tiotropium Bromide
Other Study ID Numbers
- TioDPI PuR-01 (C2A02205)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Peking University First HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Shandong Provincial Hospital and other collaboratorsRecruiting
-
Hôpital NOVORecruiting
-
Rigshospitalet, DenmarkRecruiting
-
NHS Greater Glasgow and ClydeLenus Health; University of Glasgow Robertson Centre for Bio StatisticsRecruiting
-
Xemed LLCUniversity of Pennsylvania; Temple UniversityNot yet recruiting
-
Erasme University HospitalRecruiting
-
Istituti Clinici Scientifici Maugeri SpARecruiting
-
Temple UniversityGlaxoSmithKlineNot yet recruiting
Clinical Trials on Tiotropium 18 µg inhalation powder, hard capsule
-
Orion Corporation, Orion PharmaCompletedHealthy VolunteersFinland
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveGermany
-
Orion Corporation, Orion PharmaCompleted
-
Neutec Ar-Ge San ve Tic A.ŞCompleted
-
Lung Therapeutics, IncRecruitingIdiopathic Pulmonary FibrosisUnited States, United Kingdom, Germany
-
Orion Corporation, Orion PharmaCompletedHealthy Volunteer | COPDEstonia
-
Neutec Ar-Ge San ve Tic A.ŞCompleted
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveGermany, Netherlands, Denmark, France, South Africa, Austria, Belgium, Sweden
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease | COPDUnited States